Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Costa, Tommaso | Premi, Enrico | Liloia, Donato | Cauda, Franco | Manuello, Jordi
Article Type: Research Article
Abstract: Background: Clinical trials targeting Alzheimer’s disease (AD) aim to alleviate clinical symptoms and alter the course of this complex neurodegenerative disorder. However, the conventional approach of null hypothesis significance testing (NHST) commonly employed in such trials has inherent limitations in assessing clinical significance and capturing nuanced evidence of effectiveness on a continuous scale. Objective: In this study, we conducted a re-analysis of the phase III trial of lecanemab, a recently proposed humanized IgG1 monoclonal antibody with high affinity for Aβ soluble protofibrils, using a Bayesian approach with informed t-test priors. Methods: To achieve …this, we carefully selected trial data and derived effect size estimates for the primary endpoint, the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB). Subsequently, a series of Bayes Factor analyses were performed to compare evidence supporting the null hypothesis (no treatment effect) versus the alternative hypothesis (presence of an effect). Drawing on relevant literature and the lecanemab phase III trial, we incorporated different minimal clinically important difference (MCID) values for the primary endpoint CDR-SB as prior information. Results: Our findings, based on a standard prior, revealed anecdotal evidence favoring the null hypothesis. Additional robustness checks yielded consistent results. However, when employing informed priors, we observed varying evidence across different MCID values, ultimately indicating no support for the effectiveness of lecanemab over placebo. Conclusion: Our study underscores the value of Bayesian analysis in clinical trials while emphasizing the importance of incorporating MCID and effect size granularity to accurately assess treatment efficacy. Show more
Keywords: Alzheimer’s disease, Bayes Factor, Clarity AD, clinical trial, drug development, informed t priors
DOI: 10.3233/JAD-230589
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1059-1065, 2023
Authors: Di Gioia, Claudia | Santonico, Marco | Zompanti, Alessandro | Sabatini, Anna | Grasso, Simone | Ursini, Francesca | Pedone, Claudio | Galdi, Flavia | Antonelli Incalzi, Raffaele | Pennazza, Giorgio
Article Type: Research Article
Abstract: Background: Recent studies have shown that oxidative stress plays a relevant role in Alzheimer’s disease (AD), and in the pathogenesis of vascular dementia (VaD). New diagnostic methods look for biological samples with non-invasive sampling methods. Among these, saliva shows an increase in oxidative stress products, thus a corresponding reduction in antioxidant products were found in dementia cases compared to healthy controls. Compounds identified in saliva include some hydrocarbons whose production has been related to the presence of reactive oxygen species. Objective: The hypothesis is that the voltammetric analysis performed on saliva could be a useful test for diagnosing …dementia, potentially discriminating between AD and VaD. Methods: A single-center observational study was conducted on patients referred to the dementia clinic in the Neurology area and healthy controls recruited in the Orthopedics area of the Campus Bio-Medico Hospital in Rome. The study was aimed at evaluating the discriminative properties of salivary voltammetric analysis between healthy subjects and patients with dementia and, as a secondary outcome, between AD and VaD. A total of 69 subjects were enrolled, including 29 healthy controls, 20 patients with AD, and 20 patients with VaD. The degree of cognitive impairment was classified on the basis of the Mini-Mental State Examination score. Results: The results obtained are promising, with an accuracy of 79.7%, a sensitivity of 82.5%, and a specificity of 75.8%, in the discrimination of dementia versus controls. Conclusions: The methods tested demonstrate to be relevant in the discrimination between dementia and controls. A confirmatory study is already running. Show more
Keywords: Alzheimer’s disease, cyclic voltammetry, dementia, multivariate data analysis, saliva fingerprint, vascular dementia
DOI: 10.3233/JAD-230330
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1067-1075, 2023
Authors: Li, Jinghang | Mountz, Elizabeth J. | Mizuno, Akiko | Shah, Ashti M. | Weinstein, Andrea | Cohen, Ann D. | Klunk, William E. | Snitz, Beth E. | Aizenstein, Howard J. | Karim, Helmet T.
Article Type: Research Article
Abstract: Background: Amyloid-β (Aβ) deposits asymmetrically early in Alzheimer’s disease (AD). This process is variable and has been associated with asymmetric hypometabolism. Objective: We investigated whether neural asymmetry during working memory and executive function processing was associated with AD genetic risk and markers of AD as well as other brain neuropathology biomarkers, cognitive function, and cognitive reserve in cognitively normal older adults. Methods: We analyzed data from 77 cognitively healthy, older adults who completed functional magnetic resonance imaging, positron emission tomography, and cognitive testing. We identified regions of significant activation and asymmetry during the Digital Symbol Substitution …Task (DSST). We examined associations between regions with significant hemispheric asymmetry (directional and absolute) and global cerebral Aβ, cerebral glucose metabolism, white matter hyperintensities, APOE ɛ4 allele status, DSST reaction time, age, sex, education, and cognitive function. Results: Asymmetry was not associated with several factors including cognitive function, Aβ, and white matter hyperintensities. The presence of at least one ɛ4 APOE allele in participants was associated with less asymmetric activation in the angular gyrus (right dominant activation). Greater education was associated with less asymmetric activation in mediodorsal thalamus (left dominant activation). Conclusions: Genetic risk of AD was associated with lower asymmetry in angular gyrus activation, while greater education was associated with lower asymmetry in mediodorsal thalamus activation. Changes in asymmetry may reflect components of compensation or cognitive reserve. Asymmetric neural recruitment during working memory may be related to maintenance of cognitive function in cognitively normal older adults. Show more
Keywords: Alzheimer’s disease, amyloid, asymmetry, functional brain activation, preclinical Alzheimer’s disease, working memory
DOI: 10.3233/JAD-230379
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1077-1089, 2023
Authors: Ramos, Claudia | Madrigal, Claudia | Aguirre-Acevedo, Daniel Camilo | Giraldo-Chica, Margarita | Acosta-Baena, Natalia | Aponte, Claudia | Aguillón, David | Gómez, Manuela | Espinosa, Alejandro | Madrigal, Lucia | Uribe, Claramonika | Saldarriaga, Amanda | Alzate, Diana | Ruiz, Alejandra | Andrade, Angela | Lopez, Hugo | Langbaum, Jessica B. | Sink, Kaycee M. | Reiman, Eric M. | Tariot, Pierre N. | Ríos-Romenets, Silvia | Lopera, Francisco
Article Type: Research Article
Abstract: Background: The SARS-CoV2 global pandemic impacted participants in the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) clinical trial, who faced three stressors: 1) fear of developing dementia; 2) concerns about missing treatment; and 3) risk of SARS-CoV2 infection. Objective: To describe the frequency of psychological disorders among the participants of the API ADAD Colombia clinical study, treated by a holistic mental health team during the COVID-19 pandemic. The extent of use of mental health team services was explored considering different risk factors, and users and non-users of these services were compared. Methods: Participants had …free and optional access to psychology and psychiatry services, outside of the study protocol. Descriptive statistics was used to analyze the frequency of the mental health difficulties. A multivariable logistic regression model has been used to assess associations with using this program. Results: 66 participants were treated by the Mental Health Team from March 1, 2020, to December 31, 2020. Before and after the start of the pandemic, the most common psychological problems were anxiety (36.4% before, 63.6% after) and depression (34.8% before, 37.9% after). 70% of users assisted by psychology and 81.6% of those assisted by psychiatry felt that the services were useful for them. Female sex, depression, and anxiety before the pandemic were positively associated with being assisted by either psychology or psychiatry, while the association with hyperlipidemia was negative. Conclusions: A holistic mental health program, carried out in the context of a study, could mitigate psychopathology during pandemics such as COVID-19. Show more
Keywords: Alzheimer’s disease, COVID-19, health services and institutions
DOI: 10.3233/JAD-220941
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1091-1106, 2023
Authors: Uchida, Yuto | Onda, Kengo | Hou, Zhipeng | Troncoso, Juan C. | Mori, Susumu | Oishi, Kenichi
Article Type: Research Article
Abstract: Background: Conventional neuroimaging biomarkers for the neurodegeneration of Alzheimer’s disease (AD) are not sensitive enough to detect neurodegenerative alterations during the preclinical stage of AD individuals. Objective: We examined whether neurodegeneration of the entorhinal-hippocampal pathway could be detected along the AD continuum using ultra-high-field diffusion tensor imaging and tractography for ex vivo brain tissues. Methods: Postmortem brain specimens from a cognitively unimpaired individual without AD pathological changes (non-AD), a cognitively unimpaired individual with AD pathological changes (preclinical AD), and a demented individual with AD pathological changes (AD dementia) were scanned with an …11.7T diffusion magnetic resonance imaging. Fractional anisotropy (FA) values of the entorhinal layer II and number of perforant path fibers counted by tractography were compared among the AD continuum. Following the imaging analyses, the status of myelinated fibers and neuronal cells were verified by subsequent serial histological examinations. Results: At 250μm (zipped to 125μm) isotropic resolution, the entorhinal layer II islands and the perforant path fibers could be identified in non-AD and preclinical AD, but not in AD dementia, followed by histological verification. The FA value of the entorhinal layer II was the highest among the entorhinal laminae in non-AD and preclinical AD, whereas the FA values in the entorhinal laminae were homogeneously low in AD dementia. The FA values and number of perforant path fibers decreased along the AD continuum (non-AD>preclinical AD > AD dementia). Conclusion: We successfully detected neurodegenerative alterations of the entorhinal-hippocampal pathway at the preclinical stage of the AD continuum. Show more
Keywords: Alzheimer’s disease, diffusion tensor imaging, entorhinal cortex, fiber tractography, histology, magnetic resonance imaging, neurodegeneration
DOI: 10.3233/JAD-230452
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1107-1117, 2023
Authors: Serra, Laura | Bonarota, Sabrina | Di Domenico, Carlotta | Caruso, Giulia | Giulietti, Giovanni | Caltagirone, Carlo | Cercignani, Mara | Bozzali, Marco
Article Type: Research Article
Abstract: Background: Alzheimer’s disease (AD) is the most common form of dementia worldwide. Currently there are no disease modifying treatments available. Detecting subjects with increased risk to develop dementia is essential for future clinical trials. Subjective cognitive decline (SCD) is a condition defining individuals who perceive a decrease in their own cognitive functioning in the absence of any detectable deficit on neuropsychological testing. SCD individuals show AD-related biomarkers abnormalities in cerebrospinal fluid. Objective: The aim of the present study was to assess brain functional connectivity (FC) changes in SCD individuals. Methods: 23 SCD and 33 healthy subjects …(HS) underwent an extensive neuropsychological assessment and 3T-MRI scanning including a T1-w volume and resting-state fMRI (RS-fMRI) to assess brain atrophy and brain FC. Results: No between-group differences in grey matter volumes were detected. SCD subjects compared to HS showed both increased and decreased FC in the executive and parietal networks. Associations between cognitive measures, mainly assessing working memory, and FC within brain networks were found both in SCD and HS separately. Conclusions: SCD individuals showed FC abnormalities in networks involving fronto-parietal areas that may account for their lower visuo-spatial working memory performances. Dysfunctions in executive-frontal networks may be responsible for the cognitive decline subjectively experienced by SCD individuals despite the normal scores observed by formal neuropsychological assessment. The present study contributes to consider SCD individuals in an early AD stage with an increased risk of developing the disease in the long term. Show more
Keywords: Alzheimer’s disease, brain functional connectivity, cognitive functions, magnetic resonance imaging, subjective cognitive decline
DOI: 10.3233/JAD-230536
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1119-1131, 2023
Authors: Ekenze, Oluchi | Pinheiro, Adlin | Demissie, Serkalem | Aparicio, Hugo J. | Charidimou, Andreas | Beiser, Alexa S. | Satizabal, Claudia L. | Kautz, Tiffany | DeCarli, Charles | Greenberg, Steven | Seshadri, Sudha | Romero, Jose R.
Article Type: Research Article
Abstract: Background: Neurofilament light chain (NfL) is a marker of neuronal injury. Perivascular spaces (PVS) visible on magnetic resonance imaging (MRI) represent cerebral small vessel disease (CSVD) but their role as markers of neuronal injury needs further clarification. Objective: To relate PVS burden according to brain topography and plasma NfL. Methods: Framingham Heart Study (FHS) participants with brain MRI and NfL measurements were included. PVS were rated in the basal ganglia (BG) and centrum semiovale (CSO) using validated methods and categorized based on counts. A mixed region variable representing high burden PVS in either BG or CSO …was assessed. Multivariable linear regression analyses were used to relate PVS burden to log-transformed NfL levels in models adjusted for age, sex, FHS cohort, time between MRI and clinic exam, and image view (model 1), vascular risk factors (model 2), and white matter hyperintensity volume, covert brain infarcts, and cerebral microbleeds (model 3). Results: Among 1,457 participants (68.1±8.5 years, 45% males), NfL levels increased with higher PVS burden. Multivariable analysis showed an association of high PVS burden strictly in BG with NfL (β= 0.117, 95% CI 0.014–0.221; p = 0.027), but attenuated in model 3. The associations were mainly in participants≥65 years (β= 0.122, 95% CI 0.015–0.229, p = 0.026), women (β= 0.156, 95% CI 0.024–0.288, p = 0.021), and APOE ɛ4 non-carriers (β= 0.140, 95% CI 0.017–0.263, p = 0.026). Conclusions: The association of strictly BG high PVS burden with NfL suggests a role for PVS as markers of neuroaxonal injury, but our results are hypothesis generating and require further replication. Show more
Keywords: Alzheimer’s disease, basal ganglia, cerebral small vessel disease, MRI visible perivascular spaces, neurofilament light chain, neuroaxonal injury
DOI: 10.3233/JAD-221260
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1133-1145, 2023
Authors: Hua, Simin | Peters, Brandilyn A. | Lee, Susie | Fitzgerald, Kathryn | Wang, Zheng | Sollecito, Christopher C. | Grassi, Evan | Wiek, Fanua | St Peter, Lauren | D’Souza, Gypsyamber | Weber, Kathleen M. | Kaplan, Robert C. | Gustafson, Deborah | Sharma, Anjali | Burk, Robert D. | Rubin, Leah H. | Qi, Qibin
Article Type: Research Article
Abstract: Background: Altered gut microbiota has been associated with cognitive dysfunction and Alzheimer’s disease, but little is known among people living with HIV. Objective: To examine associations between gut microbiota and cognitive impairment among women with or without HIV. Methods: This is a cross-sectional study of 446 women (302 HIV+) who had completed a neuropsychological test battery and stool sample collected within 1 year. Gut microbiota composition was quantified using 16SV4 rRNA gene sequencing and microbial functional pathways were predicted using PICRUSt. Cognitive domains included attention, executive function, learning, memory, fluency, processing speed, and motor function. Cognitive …impairment was defined as two or more domains with T scores < 1 SD below mean. ANCOM-II was used to identify taxa and functional pathways associated with cognitive impairment, and the associations were further examined by multivariable logistic regression. Results: In overall sample, adjusting for multiple covariates including HIV status, we found that higher abundance of Methanobrevibacter, Odoribacter, Pyramidobacter, Eubacterium, Ruminococcus , and Gemmiger , and lower abundance of Veillonella were associated with cognitive impairment. The associations between these taxa and cognitive impairment were more profound in HIV+ women compared to HIV- women. Most associations with bacterial taxa were observed for learning and memory. We found accompanying microbial functional differences associated with cognitive impairment, including twelve enriched pathways and three depleted pathways. Conclusions: In women with or without HIV infection, this study identified multiple altered gut bacterial taxa and functional pathways associated with cognitive impairment, supporting the potential role of gut microbiota in cognitive dysfunction and Alzheimer’s disease. Show more
Keywords: Alzheimer’s disease, cognitive impairment, gut microbiome, HIV, human, women
DOI: 10.3233/JAD-230117
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1147-1161, 2023
Authors: Makri, Marina | Gkioka, Mara | Moraitou, Despina | Fidani, Liana | Tegos, Thomas | Tsolaki, Magdalini
Article Type: Research Article
Abstract: Background: Pre-symptomatic screening methods for detecting a higher risk of Alzheimer’s disease (AD) are gaining popularity; thus, more people are seeking these tests. However, to date, not much is known about the attitudes toward pre-symptomatic AD screening. Objective: The goal of this study is to examine the psychometric properties of a tool for assessing the attitudes, barriers, and motivations to pre-symptomatic AD screening. Methods: This is a cross-sectional study performed on 208 Greek participants (189 students and 19 caregivers) provided with an online questionnaire. Psychometric properties were assessed through the examination of its construct validity (principal …component analysis) and internal consistency. Results: Exploratory factor analysis revealed the presence of four factors. The first factor is labeled as “Perceived harms of testing” (10 items), the second “Acceptance of testing” (5 items), the third “Perceived benefits of testing” (6 items), and the fourth factor “Need for knowledge” (4 items). The reliability (internal consistency) of each factor separately was acceptable to good (0.70–0.87) while the internal consistency of the overall questionnaire (25 items) was good (Cronbach’s α =0.82). Conclusion: PRE-ADS is a valid questionnaire that might help in the research of peoples’ attitudes related to the pros and cons of pre-symptomatic screening for AD, and the development of effective counseling programs and prevention strategies. However, future research is required in the target population. Show more
Keywords: Alzheimer’s disease, attitudes, benefits, perceived harms, pre-symptomatic testing, psychometrics, screening, screening acceptance, validation
DOI: 10.3233/JAD-220954
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1163-1174, 2023
Authors: Li, Zhigang | Wu, Hao | Ji, Yong | Shi, Zhihong | Liu, Shuai | Bao, Xinran | Shan, Peng | Hu, Dean | Li, Meimei
Article Type: Research Article
Abstract: Background: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease. The detection of early-stage AD is particularly desirable because it would allow early intervention. However, a minimally invasive, low-cost, and accurate discrimination or diagnostic method for AD is especially difficult in the earliest stage of AD. Objective: The aim of this research is to discover blood plasma spectral digital biomarkers of AD, develop a novel intelligent method for the discrimination of AD and accelerate the translation of Fourier transform infrared (FTIR) spectral-based disease discrimination methods from the laboratory to clinical practice. Methods: Since vibration spectroscopy can …provide the structure and chemical composition information of biological samples at the molecular level, we investigated the potential of FTIR spectral biomarkers of blood plasma to differentiate between AD patients and healthy controls. Combined with machine learning technology, we designed a hierarchical discrimination system that provides reagent-free and accurate AD discrimination based on blood plasma spectral digital biomarkers of AD. Results: Accurate segregation between AD patients and healthy controls was achieved with 89.3% sensitivity and 85.7% specificity for early-stage AD patients, 92.8% sensitivity and 87.5% specificity for middle-stage AD patients, and 100% sensitivity and 100% specificity for late-stage AD patients. Conclusions: Our results show that blood plasma spectral digital biomarkers hold great promise as discrimination markers of AD, indicating the potential for the development of an inexpensive, reagent-free, and less laborious clinical test. As a result, our research outcome will accelerate the clinical application of spectral digital biomarkers and machine learning. Show more
Keywords: Alzheimer’s disease, blood plasma, discrimination, machine learning, reagent-free, spectral digital biomarkers
DOI: 10.3233/JAD-230248
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1175-1188, 2023
Authors: Creavin, Samuel Thomas | Fish, Mark | Lawton, Michael | Cullum, Sarah | Bayer, Antony | Purdy, Sarah | Ben-Shlomo, Yoav
Article Type: Research Article
Abstract: Background: Many health systems are interested in increasing the number of uncomplicated and typical dementia diagnoses that are made in primary care, but the comparative accuracy of tests is unknown. Objective: Calculate diagnostic accuracy of brief cognitive tests in primary care. Methods: We did a diagnostic test accuracy study in general practice, in people over 70 years who had consulted their GP with cognitive symptoms but had no prior diagnosis of dementia. The reference standard was specialist assessment, adjudicated for difficult cases, according to ICD-10. We assessed 16 index tests at a research clinic, and additionally …analyzed referring GPs clinical judgement. Results: 240 participants had a median age of 80 years, of whom 126 were men and 132 had dementia. Sensitivity of individual tests at the recommended thresholds ranged from 56% for GP judgement (specificity 89%) to 100% for MoCA (specificity 16%). Specificity of individual tests ranged from 4% for Sniffin’ sticks (sensitivity 100%) to 91% for Timed Up and Go (sensitivity 23%). The 95% centile of test duration in people with dementia ranged from 3 minutes for 6CIT and Time and Change, to 16 minutes for MoCA. Combining tests with GP judgement increased test specificity and decreased sensitivity: e.g., MoCA with GP Judgement had specificity 87% and sensitivity 55%. Conclusions: Using GP judgement to inform selection of tests was an efficient strategy. Using IQCODE in people who GPs judge as having dementia and 6CIT in people who GPs judge as having no dementia, would be a time-efficient and accurate diagnostic assessment. The original protocol for the study is available at https://bmcfampract.biomedcentral.com/articles/10.1186/s12875-016-0475-2 Show more
Keywords: Alzheimer’s disease, dementia, general practice, sensitivity and specificity, symptom assessment
DOI: 10.3233/JAD-230320
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1189-1200, 2023
Authors: Zhang, Jingwen | Liu, Qing | Zhang, Haorui | Dai, Michelle | Song, Qianqian | Yang, Defu | Wu, Guorong | Chen, Minghan
Article Type: Research Article
Abstract: Background: Despite the striking efforts in investigating neurobiological factors behind the acquisition of amyloid-β (A), protein tau (T), and neurodegeneration ([N]) biomarkers, the mechanistic pathways of how AT[N] biomarkers spreading throughout the brain remain elusive. Objective: To disentangle the massive heterogeneities in Alzheimer’s disease (AD) progressions and identify vulnerable/critical brain regions to AD pathology. Methods: In this work, we characterized the interaction of AT[N] biomarkers and their propagation across brain networks using a novel bistable reaction-diffusion model, which allows us to establish a new systems biology underpinning of AD progression. We applied our model to large-scale …longitudinal neuroimages from the ADNI database and studied the systematic vulnerability and criticality of brains. Results: Our model yields long term prediction that is statistically significant linear correlated with temporal imaging data, produces clinically consistent risk prediction, and captures the Braak-like spreading pattern of AT[N] biomarkers in AD development. Conclusions: Our major findings include (i) tau is a stronger indicator of regional risk compared to amyloid, (ii) temporal lobe exhibits higher vulnerability to AD-related pathologies, (iii) proposed critical brain regions outperform hub nodes in transmitting disease factors across the brain, and (iv) comparing the spread of neuropathological burdens caused by amyloid-β and tau diffusions, disruption of metabolic balance is the most determinant factor contributing to the initiation and progression of AD. Show more
Keywords: Alzheimer’s disease, AT[N] biomarkers, brain network, reaction-diffusion model, vulnerable and critical regions
DOI: 10.3233/JAD-230027
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1201-1219, 2023
Authors: Oyarzún-González, Ximena | Abner, Erin L. | Toro, Pablo | Ferreccio, Catterina
Article Type: Research Article
Abstract: Background: Subjective memory complaints (SMC) are commonly studied in older adults and have been identified as potentially prodromal to dementia and Alzheimer’s disease. Studies among younger adults from South America are lacking. Objective: To estimate the prevalence of SMC and the factors associated with it among Maule Cohort (MAUCO) participants. Methods: We performed a cross-sectional analysis to estimate the prevalence of SMC and investigated its associated factors from MAUCO baseline data (N = 6,687). Within groups defined by age (38–59, 60–74) and global cognition (Mini-Mental State Examination: ≥26, 25-22, ≤21), multinomial logistic regression models evaluated risk factors for …SMC (Yes, Sometimes, No). Results: Overall, SMC prevalence was 16.4%; 15.9% (95% CI 14.9–16.9%) among younger and 17.6% (15.8–19.4%) among older participants. Female sex, comorbidities, and bad/fair self-reported health status (SRHS) were generally associated with higher odds of SMC. Conclusion: Overall prevalence of SMC was 16%. Different factors were associated with the odds of SMC depending on age and global cognitive status. Future SMC studies should include sex-specific assessments, evaluate SRHS as a moderator of SMC reporting, and the influence of the SARS-CoV-2 pandemic on SMC reporting. Show more
Keywords: Alzheimer’s disease, cohort, MAUCO, memory, multinomial, subjective memory complaint
DOI: 10.3233/JAD-230541
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1221-1231, 2023
Authors: Koppelmans, Vincent | Ruitenberg, Marit F.L. | Schaefer, Sydney Y. | King, Jace B. | Hoffman, John M. | Mejia, Amanda F. | Tasdizen, Tolga | Duff, Kevin
Article Type: Research Article
Abstract: Background: Despite reports of gross motor problems in mild cognitive impairment (MCI) and Alzheimer’s disease (AD), fine motor function has been relatively understudied. Objective: We examined if finger tapping is affected in AD, related to AD biomarkers, and able to classify MCI or AD. Methods: Forty-seven cognitively normal, 27 amnestic MCI, and 26 AD subjects completed unimanual and bimanual computerized tapping tests. We tested 1) group differences in tapping with permutation models; 2) associations between tapping and biomarkers (PET amyloid-β, hippocampal volume, and APOE ɛ 4 alleles) with linear regression; and 3) the predictive value …of tapping for group classification using machine learning. Results: AD subjects had slower reaction time and larger speed variability than controls during all tapping conditions, except for dual tapping. MCI subjects performed worse than controls on reaction time and speed variability for dual and non-dominant hand tapping. Tapping speed and variability were related to hippocampal volume, but not to amyloid-β deposition or APOE ɛ 4 alleles. Random forest classification (overall accuracy = 70%) discriminated control and AD subjects, but poorly discriminated MCI from controls or AD. Conclusions: MCI and AD are linked to more variable finger tapping with slower reaction time. Associations between finger tapping and hippocampal volume, but not amyloidosis, suggest that tapping deficits are related to neuropathology that presents later during the disease. Considering that tapping performance is able to differentiate between control and AD subjects, it can offer a cost-efficient tool for augmenting existing AD biomarkers. Show more
Keywords: Alzheimer’s disease, biomarkers, finger tapping, manual dexterity, motor function
DOI: 10.3233/JAD-221297
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1233-1252, 2023
Authors: Fazlollahi, Amir | Lee, Soohyun | Coleman, Felicia | McCann, Emily | Cloos, Martijn A. | Bourgeat, Pierrick | Nestor, Peter J.
Article Type: Research Article
Abstract: Background: Objective measurement of regional cortical atrophy in individual patients would be a highly desirable adjunct for diagnosis of degenerative dementias. Objective: We hypothesized that increasing the resolution of magnetic resonance scans would improve the sensitivity of cortical atrophy detection for individual patients. Methods: 46 participants including 8 semantic-variant primary progressive aphasia (svPPA), seven posterior cortical atrophy (PCA), and 31 cognitively unimpaired participants underwent clinical assessment and 3.0T brain scans. SvPPA and PCA were chosen because there is overwhelming prior knowledge of the expected atrophy pattern. Two sets of T1-weighted images with 0.8 mm3 (HighRes) …and conventional 1.0 mm3 (ConvRes) resolution were acquired. The cortical ribbon was segmented using FreeSurfer software to obtain surface-based thickness maps. Inter-sequence performance was assessed in terms of cortical thickness and sub-cortical volume reproducibility, signal-to-noise and contrast-to-noise ratios. For clinical cases, diagnostic effect size (Cohen’s d) and lesion distribution (z-score and t-value maps) were compared between HighRes and ConvRes scans. Results: The HighRes scans produced higher image quality scores at 90 seconds extra scan time. The effect size of cortical thickness differences between patients and cognitively unimpaired participants was 15–20% larger for HighRes scans. HighRes scans showed more robust patterns of atrophy in expected regions in each and every individual patient. Conclusions: HighRes T1-weighted scans showed superior precision for identifying the severity of cortical atrophy in individual patients, offering a proof-of-concept for clinical translation. Studying svPPA and PCA, two syndromes with well-defined focal atrophy patterns, offers a method to clinically validate and contrast automated algorithms. Show more
Keywords: Alzheimer’s disease, atrophy, cortical thickness, degeneration, dementia, dementia diagnosis, MPRAGE
DOI: 10.3233/JAD-230030
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1253-1262, 2023
Authors: Kim, Dong-Yun | Kim, Jae Sik | Seo, Young-Seok | Park, Woo-Yoon | Kim, Byoung Hyuck | Hong, Eun-Hee | Kim, Ji Young | Cho, Seong-Jun | Rhee, Hak Young | Kim, Aryun | Kim, Keun You | Oh, Dae Jong | Chung, Weon Kuu
Article Type: Research Article
Abstract: Background: Alzheimer’s disease (AD), the most common cause of dementia, is a neurodegenerative disease resulting from extracellular and intracellular deposits of amyloid-β (Aβ) and neurofibrillary tangles in the brain. Although many clinical studies evaluating pharmacological approaches have been conducted, most have shown disappointing results; thus, innovative strategies other than drugs have been actively attempted. Objective: This study aims to explore low-dose radiation therapy (LDRT) for the treatment of patients with AD based on preclinical evidence, case reports, and a small pilot trial in humans. Methods: This study is a phase II, multicenter, prospective, …single-blinded, randomized controlled trial that will evaluate the efficacy and safety of LDRT to the whole brain using a linear accelerator in patients with mild AD. Sixty participants will be randomly assigned to three groups: experimental I (24 cGy/6 fractions), experimental II (300 cGy/6 fractions), or sham RT group (0 cGy/6 fractions). During LDRT and follow-up visits after LDRT, possible adverse events will be assessed by the physician’s interview and neurological examinations. Furthermore, the effectiveness of LDRT will be measured using neurocognitive function tests and imaging tools at 6 and 12 months after LDRT. We will also monitor the alterations in cytokines, Aβ42 /Aβ40 ratio, and tau levels in plasma. Our primary endpoint is the change in cognitive function test scores estimated by the Alzheimer’s Disease Assessment Scale-Korea compared to baseline after 6 months of LDRT. Conclusions: This study is registered at ClinicalTrials.gov [NCT05635968] and is currently recruiting patients. This study will provide evidence that LDRT is a new treatment strategy for AD. Show more
Keywords: Alzheimer’s disease, low-dose radiation therapy, protocol, randomized controlled trial
DOI: 10.3233/JAD-230241
Citation: Journal of Alzheimer's Disease, vol. 95, no. 3, pp. 1263-1272, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]